Skip to main content

Table 2 Overall and subgroup meta-analyses of the relationship between mGPS and OS

From: The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Subgroups

Studies/N

Patients/N

Pooled HR (95% CI, P)

Heterogeneity (P, I², Model)

mGPS: high vs. low

 Overall

12

2009

1.504, (1.197–1.891), < 0.0001

0.003, 61.7%, random

 Region

    

 East

9

1668

1.597, (1.240–2.056), < 0.0001

0.071, 44.7%, fixed

 West

3

341

1.342, (0.797–2.258), 0.268

0.002, 83.8%, random

 Therapy

    

 Chemotherapy

7

932

1.455, (1.048–2.020), 0.025

0.001, 74.2%, random

 Pancreatectomy

5

1077

1.638, (1.247–2.150), < 0.0001

0.345, 10.7%, fixed

mGPS: 1 vs. 0

 Overall

8

4503

1.683, (1.247–2.269), 0.001

< 0.0001, 86.6%, random

 Region

    

 East

7

4401

1.711, (1.248–2.347), 0.001

< 0.0001, 88.5%, random

 West

1

102

1.346, (0.585–3.098), 0.485

 Therapy

    

 Chemotherapy

6

2968

1.780, (1.297–2.443), < 0.0001

< 0.0001, 83.9%, random

 Pancreatectomy

2

1535

1.521, (0.602–3.838), 0.375

0.001, 91.4%, random

mGPS: 2 vs. 0

 Overall

8

4503

1.899, (1.356–2.660), < 0.0001

< 0.0001, 80.4%, random

 Region

    

 East

7

4401

1.833, (1.285–2.615), 0.001

< 0.0001, 82.3%, random

 West

1

102

2.712, (1.252–5.875), 0.011

 Therapy

    

 Chemotherapy

6

2968

1.872, (1.174–2.984), 0.008

< 0.0001, 81.5%, random

 Pancreatectomy

2

1535

2.011, (0.941–4.297), 0.078

0.003, 88.3%, rrandom

  1. “–” means not available; N means number